New pill for schizophrenia and depression passes early safety check
NCT ID NCT07549581
First seen May 01, 2026 · Last updated May 17, 2026 · Updated 3 times
Summary
This early-stage study tested a new oral drug, SEP-380135, in 43 adults with schizophrenia or major depression (including bipolar disorder). The main goal was to check if the drug is safe and how the body processes it. Participants took multiple doses and were closely monitored for side effects, mood changes, and vital signs. This is a first step to see if the drug is promising enough for larger trials.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MAJOR DEPRESSIVE DISORDER (MDD) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Collaborative Neuroscience Research, LLC
Los Alamitos, California, 90720, United States
Conditions
Explore the condition pages connected to this study.